125 related articles for article (PubMed ID: 18199808)
1. Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil.
Bessay EP; Blount MA; Zoraghi R; Beasley A; Grimes KA; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2008 Apr; 325(1):62-8. PubMed ID: 18199808
[TBL] [Abstract][Full Text] [Related]
2. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
[TBL] [Abstract][Full Text] [Related]
3. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
4. Conformational conversion of PDE5 by incubation with sildenafil or metal ion is accompanied by stimulation of allosteric cGMP binding.
Corbin JD; Francis SH
Cell Signal; 2011 Oct; 23(10):1578-83. PubMed ID: 21620965
[TBL] [Abstract][Full Text] [Related]
5. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
6. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
7. Radiolabeled ligand binding to the catalytic or allosteric sites of PDE5 and PDE11.
Weeks JL; Blount MA; Beasley A; Zoraghi R; Thomas MK; Sekhar KR; Corbin JD; Francis SH
Methods Mol Biol; 2005; 307():239-62. PubMed ID: 15988068
[TBL] [Abstract][Full Text] [Related]
8. [3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.
Corbin JD; Blount MA; Weeks JL; Beasley A; Kuhn KP; Ho YS; Saidi LF; Hurley JH; Kotera J; Francis SH
Mol Pharmacol; 2003 Jun; 63(6):1364-72. PubMed ID: 12761347
[TBL] [Abstract][Full Text] [Related]
9. Allosteric-site and catalytic-site ligand effects on PDE5 functions are associated with distinct changes in physical form of the enzyme.
Corbin JD; Zoraghi R; Francis SH
Cell Signal; 2009 Dec; 21(12):1768-74. PubMed ID: 19665054
[TBL] [Abstract][Full Text] [Related]
10. Hydropathic analysis and mutagenesis of the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). cGMP versus cAMP substrate selectivity.
Turko IV; Francis SH; Corbin JD
Biochemistry; 1998 Mar; 37(12):4200-5. PubMed ID: 9521742
[TBL] [Abstract][Full Text] [Related]
11. Mechanisms of action of PDE5 inhibition in erectile dysfunction.
Corbin JD
Int J Impot Res; 2004 Jun; 16 Suppl 1():S4-7. PubMed ID: 15224127
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities.
Corbin JD; Turko IV; Beasley A; Francis SH
Eur J Biochem; 2000 May; 267(9):2760-7. PubMed ID: 10785399
[TBL] [Abstract][Full Text] [Related]
13. A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5).
Corbin JD; Beasley A; Turko IV; Haik TL; Mangum KA; Wells JN; Francis SH; Sekhar KR
Cell Biochem Biophys; 1998; 29(1-2):145-57. PubMed ID: 9631243
[TBL] [Abstract][Full Text] [Related]
14. Metal ion stimulators of PDE5 cause similar conformational changes in the enzyme as does cGMP or sildenafil.
Corbin JD; Foster TL; Bessay E; Busch J; Blount M; Francis SH
Cell Signal; 2011 May; 23(5):778-84. PubMed ID: 21187142
[TBL] [Abstract][Full Text] [Related]
15. cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5.
Kotera J; Grimes KA; Corbin JD; Francis SH
Biochem J; 2003 Jun; 372(Pt 2):419-26. PubMed ID: 12617722
[TBL] [Abstract][Full Text] [Related]
16. Tadalafil, a long-acting type 5 phosphodiesterase isoenzyme inhibitor, improves neurological functional recovery in a rat model of embolic stroke.
Zhang L; Zhang Z; Zhang RL; Cui Y; LaPointe MC; Silver B; Chopp M
Brain Res; 2006 Nov; 1118(1):192-8. PubMed ID: 16959227
[TBL] [Abstract][Full Text] [Related]
17. Expression and regulation of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) in human colonic epithelial cells: role in the induction of cellular refractoriness to the heat-stable enterotoxin peptide.
Bakre MM; Sopory S; Visweswariah SS
J Cell Biochem; 2000 Feb; 77(1):159-67. PubMed ID: 10679826
[TBL] [Abstract][Full Text] [Related]
18. The GAF domain of the cGMP-binding, cGMP-specific phosphodiesterase (PDE5) is a sensor and a sink for cGMP.
Biswas KH; Sopory S; Visweswariah SS
Biochemistry; 2008 Mar; 47(11):3534-43. PubMed ID: 18293931
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil.
Bessay EP; Zoraghi R; Blount MA; Grimes KA; Beasley A; Francis SH; Corbin JD
Front Biosci; 2007 Jan; 12():1899-910. PubMed ID: 17127429
[TBL] [Abstract][Full Text] [Related]
20. Allosteric sites of phosphodiesterase-5 sequester cyclic GMP.
Kotera J; Francis SH; Grimes KA; Rouse A; Blount MA; Corbin JD
Front Biosci; 2004 Jan; 9():378-86. PubMed ID: 14766375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]